Simulations Plus Releases Major Upgrade in ADMET Predictor 5.0

LANCASTER, Calif.–(BUSINESS WIRE)–Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, has released a major upgrade for its best-in-class ADMET Predictor™ software for predicting properties of molecules with only their structures as inputs.

Dr. Robert Fraczkiewicz, team leader for ADMET Cheminformatics at Simulations Plus, said, “This new release of ADMET Predictor, Version 5.0, is the result of over a year of work that builds upon our Small Business Innovation Research grant from the National Institutes of Health, as well as many man-months of work under our internally funded R&D. ADMET Predictor was already ranked at the top of every independent published comparison study in predictive accuracy, and we are confident this upgrade will build on that success and expand our competitive advantage in the marketplace.”

ADMET Predictor Version 5.0 incorporates:

  • A series of new predictive models that broaden the scope of the offering
  • Completely retrained existing models with further improved accuracy
  • New and updated molecular and atomic descriptors used in training the models
  • A number of convenience improvements to the user interface
  • New output options for better visualization of results
  • Improved model-building capabilities in its ADMET Modeler™ module

Walt Woltosz, chairman and chief executive officer of Simulations Plus, added, “This new release of ADMET Predictor is important not only for what the program can do by itself, but also because it integrates with two of our other major software offerings and thereby enhances three products rather than just one. GastroPlus™ and MedChem Studio™ (formerly ClassPharmer™) both can call ADMET Predictor in the background to generate predicted properties for use in their respective analyses. We are confident ADMET Predictor’s advantage over the competition has now been extended even further with version 5.0.”

About Simulations Plus, Inc.

Simulations Plus, Inc. is a premier developer of groundbreaking drug discovery and development simulation and modeling software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. The Company’s Words+, Inc., wholly owned subsidiary provides augmentative communication systems and other technologies for persons with disabilities. Simulations Plus is headquartered in Southern California. For more information, visit our web site at www.simulations-plus.com.